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_________________________________________________________________________________________________________________	
BACKGROUND	 	 	 	 	
Aplastic	Anemia	is	a	rare	disorder	that	affects	
the	hematopoietic	stem	cell.	This	results	 in	a	
decrease	 of	 cell	 production	 in	 the	 bone	
marrow	leading	to	Anemia.	This	is	caused	by	
the	 immune	 system	 attacking	 the	




or	 even	 be	 a	 lifelong	 disorder	 (Georges,	
Doney,	&	Storb,	2018).	In	2013	A	twenty-one-
year-old	 male	 athlete	 reported	 having	
headaches	 and	 fatigue.	 With	 continuing	
performance	 issues,	 headaches,	 and	 fatigue	
the	 athlete	 had	 bloodwork	 done.	 He	 was	
diagnosed	 with	 severe	 Aplastic	 anemia,	
differential	 diagnosis	 consists	 of	 paroxysmal	
nocturnal	 hemoglobinuria,	 and	
myelodysplastic	 syndrome.	 These	 were	
possible	 diagnosis	 due	 to	 the	 similarities	 of	
the	disorder	and	similar	signs	and	symptoms	
from	headaches	and	fatigue	to	easily	bruising.		
TREATMENT	 	 	 	 														
The	athlete	 completed	a	Prednisone	 tapered	
treatment	 over	 a	 one-month	 period	 and	
continued	 with	 treating	 the	 condition	 with	
Cyclosporin	for	an	additional	six-months.	The	
athlete’s	symptoms	returned	shortly	after	that	
and	 he	 was	 no	 longer	 responsive	 to	
immunosuppressant	 treatments	 when	 re-
introduced	 to	 the	 immunosuppressants.	 On	
April	thirteenth,	2017	the	athlete	underwent	
a	 haploidentical	 hematopoietic	 stem	 cell	
transplant	 with	 his	 biological	 father	 as	 the	
donor.	 After	 the	 transplant	 the	 athlete	
presented	 with	 Epstein-Barr	 virus	 and	
received	a	dosage	of	Rituximab	about	a	month	
after	the	transplant.	The	athlete	stayed	in	the		
hospital	 for	 thirteen	 days	 while	 getting	
continued	 immunosuppressant	 medication	
and	vitals	monitored	during	this	time.		
OUTCOMES	 	 	 	 	 	
Eventually	 the	 athlete	was	 able	 to	 gradually	
stop	 taking	 immunosuppressants	 and	 blood	
work	 was	 within	 normal	 ranges	 with	 no	
evidence	 of	 Epstein-Batt	 virus	 or	 Graft-
versus-host	disease.	The	transplant	and	post-
surgical	 treatments	 were	 successful	 in	




season	 the	 athlete	 started	his	 return	 to	play	
regiment.	This	consisted	of	monthly	physician	
checkups	and	close	monitorization	of	activity.	
The	 physical	 activities	 that	 were	 allowed	
varied	 on	 how	 the	 athlete	 felt	 along	 with	
clinician	 feedback	 from	 the	 physician.	 Since	
this	is	an	autoimmune	disorder	the	athlete	is	
instructed	 to	 report	 any	 out	 of	 the	 normal	
signs	and	symptoms	to	make	sure	the	Aplastic	
anemia	 does	 not	 return.	 Since	 it’s	 an	
autoimmune	disorder	 if	 the	athlete	becomes	
sick	intervention	is	necessary	to	prevent	any	
complications	 with	 this	 disorder.	 Prior	 to	
every	game	the	athlete	must	check	 in	with	a	
team	 doctor	 and	 get	 cleared	 to	 play.	 When	
working	 with	 the	 patient	 the	 physician	 and	
athletic	trainers	must	keep	a	constant	look	for	
excessive	fatigue	and	other	related	symptoms	
of	 Aplastic	 anemia	 to	 try	 and	 prevent	 the	
disorder	from	returning.	His	rehab	and	return	
to	 play	 regiment	 was	 not	 limited	 due	 to	 an	
injury	 so	 it	was	 primarily	 based	 on	 his	 own	






UNIQUENESS		 	 	 	 	
The	 fact	 that	 the	athlete	had	 this	disorder	 is	
unique	 within	 its	 self	 because	 this	 is	 a	 rare	
disorder.	 This	 disorder	 has	 no	 known	 exact	
incident	 rare	 but	 average	 around	 1.5	 to	 7	
cases	 out	 of	 one	 million	 people	 worldwide	
(Vaht,	Krista,	et	al.	2017).	You	usually	need	a	
bone	 marrow	 donor	 to	 help	 treat	 it	 with	 a	
more	permanent	solution.		
CONCLUSIONS	 	 	 	 	
The	athlete	was	diagnosed	 in	2013	and	with	
transplants	 and	 medical	 intervention	 was	
cured	 of	 his	 Aplastic	 anemia	 in	 2017.	 By	
following	 return	 to	 play	 procedures	
implemented	 by	 the	 athletic	 trainer	 and	
physician	he	was	able	to	start	participating	in	
college	 football	again.	 It	 is	 important	 to	note	
that	 constant	 checkups	 were	 required	 to	
monitor	 the	disorder	 and	prevent	 it	 from	 re	
occurring.	 Ways	 to	 apply	 this	 in	 a	 clinical	
setting	 is	 making	 sure	 proper	 protocol	 and	
steps	 are	 taken	 to	 help	 diagnose	 treat	 and	
prevent	 further	 issues	 not	 only	 in	 this	
situation.		
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